Pregabalin litigation - why did the SPCs lapse?

No items found.
​
31 May 2018
Tags
Life
Table of contents
  • Toc Heading
  • Toc Heading

Writing in the GRUR Newsletter ahead of the decision of the Supreme Court on the validity of a European patent owned by a subsidiary of Pfizer, covering the use of pregabalin in the treatment of pain, Darren Smyth looks at the various theories as to why the related SPCs were allowed to lapse.

Related articles

See all articles

EIP Recognised in The Times Best Law Firms 2026
03 December 2025
EIP is proud to be featured in The Times Best Law Firms 2026, a prestigious list based on peer recommendations across the legal industry. This recognition highlights EIP’s commitment to technical excellence, client-focused service, and innovative IP strategies. From high-value patent litigation to strategic portfolio management, EIP continues to deliver results that matter for clients in technology, life sciences, and engineering. This accolade reinforces our position as a trusted leader in intellectual property law.
​
EIP Launches Tech & AI Function to Drive Innovation and Client Excellence
06 November 2025
When it comes to technology, EIP has always been ahead of the curve; we are proud to announce the evolution of our IT department into a dedicated Tech & AI function, marking a bold step towards...
​
EIP shortlisted for The British Legal Awards 2025
26 September 2025
We are proud to share that we've been shortlisted for The British Legal Awards 2025 in the newly introduced category: ‘IP Team of the Year'! A special shout-out to our fantastic Litigation team,...
​